Categories: News

Aon Appoints Jo Ann Jenkins to Board of Directors

DUBLIN, Aug. 4, 2025 /PRNewswire/ — Aon plc (NYSE: AON), a leading global professional services firm, today announced that Jo Ann Jenkins has been appointed to its Board of Directors, effective August 15, 2025.

- Advertisement -

“We are pleased to welcome Jo Ann Jenkins to Aon’s Board of Directors,” said Board Chair Lester B. Knight. “Jo Ann’s experience leading large nonprofit and public sector organizations will bring new insights to our Board as we look to deliver more value for Aon’s clients, colleagues and shareholders.”

- Advertisement -

Jenkins previously served as CEO of AARP, the world’s largest nonprofit, nonpartisan membership organization dedicated to social change and helping people 50 and over to improve the quality of their lives. Among her accomplishments at AARP, Jenkins championed the multigenerational workforce, healthy longevity, protecting Social Security and Medicare and lowering the cost of prescription drugs. She led through a spirit of innovation, creating AgeTech and launching a Digital First journey to help AARP better serve its members in the future. Prior to her appointment as CEO, Jenkins served as AARP’s COO and before that as president of AARP Foundation. Before joining AARP, Jenkins served at the Library of Congress as COO and Chief of Staff. She has also held a variety of senior roles at the U.S. Department of Agriculture, the U.S. Department of Transportation, and the U.S. Department of Housing and Urban Development.

- Advertisement -

Jenkins also serves on the board of General Mills and Avnet and has held a variety of board and advisory positions, including with AARP Services, AARP Funds, Colonial Williamsburg Foundation, the Wall Street Journal CEO Council, Kennedy Center National Symphony Orchestra Board of Directors, Stanford School of Medicine Board of Fellows, U.S. Small Business Administration Council on Underserved Communities and Caring for Military Families. Fortune magazine named Jenkins as “One of the World’s 50 Greatest Leaders” in 2019 and 2021 and she is the author of the best-selling book, Disrupt Aging: A Bold New Path to Living Your Best Life at Every Age.

- Advertisement -

“It is exciting to join Aon’s Board as the firm accelerates its strategy to help organizations around the world address interconnected risk and people issues in an increasingly complex and uncertain environment,” said Jenkins. “I am looking forward to sharing my perspective and working together with Aon’s board and executive leadership to unlock further opportunities for the firm’s clients to empower their people and protect and grow their businesses.”

- Advertisement -

For more information about Aon’s corporate governance practices and Board of Directors, please click here.

- Advertisement -

About Aon

- Advertisement -

Aon plc (NYSE: AON) exists to shape decisions for the better — to protect and enrich the lives of people around the world. Through actionable analytic insight, globally integrated Risk Capital and Human Capital expertise, and locally relevant solutions, our colleagues provide clients in over 120 countries with the clarity and confidence to make better risk and people decisions that protect and grow their businesses.

- Advertisement -

Follow Aon on LinkedInXFacebook and Instagram. Stay up-to-date by visiting Aon’s newsroom and sign up for news alerts here.

- Advertisement -

Media Contact

- Advertisement -

mediainquiries@aon.com
Toll-free (U.S., Canada and Puerto Rico): +1 833 751 8114
International: +1 312 381 3024

- Advertisement -

Logo – https://mma.prnewswire.com/media/1632623/Aon_Logo_2.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/aon-appoints-jo-ann-jenkins-to-board-of-directors-302520840.html

- Advertisement -

Recent Posts

Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: Ocular Therapeutix, Inc. BEDFORD, Mass., Feb. 06, 2026…

3 hours ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026 16:01 ET  | Source: NewAmsterdam Pharma N.V. NAARDEN, The Netherlands and MIAMI,…

3 hours ago

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing…

3 hours ago

The Ministry of Finance and the International Monetary Fund to launch tomorrow the second edition of the AlUla Conference for Emerging Market Economies

AlUla, Saudi Arabia, Feb. 7, 2026 /PRNewswire/ -- The second edition of the AlUla Conference…

3 hours ago

Roches fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…

3 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

February 06, 2026 17:17 ET  | Source: Lexicon Pharmaceuticals, Inc. THE WOODLANDS, Texas, Feb. 06,…

3 hours ago